<scp>ACT001</scp> Inhibits Tumor Progression and Modulates Immune Responses in Non‐Small Cell Lung Cancer
ACT001 exhibits antitumoral and immunomodulatory potential by targeting STAT1/STAT3 and regulating PD-L1, offering a promising therapeutic approach for NSCLC.
Authors
- Huijie Hou (ORCID: https://orcid.org/0000-0002-6968-8080)
- Zhe Chen (ORCID: https://orcid.org/0000-0002-1668-4051)
- Zhitao Wang (ORCID: https://orcid.org/0000-0002-1501-1891)
- Yiman Li (ORCID: https://orcid.org/0009-0000-7243-6784)
- Hui Guo (ORCID: https://orcid.org/0000-0003-0293-6534)
- Yan Song (ORCID: https://orcid.org/0000-0002-1720-227X)
- Zhijing Shi
- Yang Yu (ORCID: https://orcid.org/0000-0002-2588-5875)
Institutions
- Tianjin Medical University General Hospital (CN)
- Tianjin Chest Hospital (CN)
Publication Details
- Journal
- Journal of Clinical Laboratory Analysis
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1002/jcla.70066
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Tianjin Municipal Health Commission
- Tianjin Medical University